On-Demand: Let’s Talk: Moving CGTx Clinical Development Forward in 2023
Sponsored by Precision ADVANCE, this Endpoints webinar will convene leading advanced therapy experts to discuss the future of CGTx clinical development. This discussion will be moderated by Teresa Pokladowski: Regional VP, Clinical Business Solutions (Precision for Medicine), and include insights from Kinnari Patel: President & COO (Rocket Pharmaceuticals), Suma Krishnan: Founder & President (Kystal Biotech), Dawn Buchanan: VP Clinical Operations (AffyImmune), and Ramona Repaczki-Jones: Executive Director, Commercial Treatment Center Operations, Cell Therapy (lovance Biotherapeutics, Inc).
Precision for Medicine CIR (French Research Tax Credit) Accreditation Updates
PARIS, FRANCE – 10 November 2022 — Precision for Medicine, the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively, today announced that it has received updated CIR accreditation from the French Ministry of Higher Education and Research.
The French R&D tax credit initiative (‘Crédit d’Impôt Recherche’, CIR) gives eligible research-based French companies, who are subject to corporate tax in France, the ability to claim tax relief on costs generated in R&D activities outsourced to Precision for Medicine.
Under this accreditation, the French Ministry of Higher Education and Research has also recognized Precision for Medicine’s Italian, German, Polish, Spanish, and Hungarian affiliates as reputable cross-border R&D experts.
Andrea Cotton-Berry, Precision for Medicine’s Global Head of Strategic Development, commented: “We are thrilled to receive this accreditation as it allows our current and future clients in France to benefit from a tax relief of up to 30% of their R&D expenditure committed to Precision for Medicine.”
About Precision for Medicine
Precision for Medicine supports life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies novel biomarker approaches to clinical research that take advantage of the latest advancements in science and technology, focusing predominantly on genomics, immune-response assays, global specimen logistics, biomarker analytics, companion diagnostics, and clinical trial execution. Precision for Medicine is part of Precision Medicine Group, with over 3,000 employees in 40 locations across North America, Europe and APAC. For more information, visit precisionformedicine.com.
# # #
Contact:
Estelle Roger, Precision Medicine Group Senior Program Manager
estelle.roger@precisionmedicinegrp.com
White Paper: What’s Next for Cell and Gene Therapies in 2023 and Beyond
The cell and gene therapy (CGTx) sector has flourished in recent years due to continued investor confidence. However, the present downturn in public markets has negatively affected that confidence, raising questions about the sector’s prospects for 2023 and beyond.
This white paper is based on a panel discussion at the Cell & Gene Meeting on the Mesa (October 11, 2022), sponsored by Precision ADVANCE, focusing on the future of advanced therapies. The panel included insights from the following industry leaders:
- Anshul Mangal: President (Project Farma & Precision ADVANCE)
- Stewart Abbot: Chief Scientific Officer (Turnstone Biologics)
- Laura Lande-Diner: Chief Business Officer (Satellite Bio)
- Robert Peters: Chief Scientific Officer (Ensoma)
- Deborah Phippard: Chief Scientific Officer (Precision For Medicine)
White Paper: State of the Union for Advanced Medicines
The cell and gene therapy (CGTx) sector has flourished over the last 2 to 5 years due to continued investor confidence. However, the recent downturn in public markets has undermined that confidence.
This white paper is based on a panel discussion, sponsored by Precision ADVANCE, featuring insights from diverse industry perspectives on the current state of the CGTx sector; the investment landscape; scientific and technical advances; progress in drug development, manufacturing, regulatory, pricing, and reimbursement; and expected key trends in 2023 and beyond. Hosted by Endpoints News, the panel included insights from the following industry leaders:
- Anshul Mangal: President (Project Farma & Precision ADVANCE)
- Dave Greenwald: Vice President of Business Development (Deerfield Management)
- Rajul Jain: Managing Director (Vida Ventures)
- Joseph LaBarge: Chief Executive Officer (Apertura Gene Therapy)
- Adrian Woolfson: Executive Chairman, President and Co-Founder (Replay Bio)
- Phil Cyr: Executive Vice President (Precision Value & Health)
QuartzBio, a Part of Precision for Medicine, Acquires SolveBio and Expands Software-as-a-Service (SaaS) Data Management Solutions for Clinical Research & Development (R&D)
QuartzBio’s suite of end-to-end SaaS solutions provides pharmaceutical and biotech clients with a fully connected data ecosystem linking sample, biomarker, and clinical data to improve collaboration, planning and R&D productivity.
[Frederick, MD – January 24, 2023] Precision for Medicine, the first global, precision medicine clinical research services organization, today announced the strategic acquisition of SolveBio by QuartzBio.
SolveBio’s intelligent technologies and enterprise data management platform has integrated into QuartzBio’s suite of SaaS solutions, providing a single, scalable solution supporting clinical sample inventory management and biomarker data management for the biotech and pharmaceutical sectors.